4-(2-dimethylcarbamoyl-ethyl)-2-methyl-1H-pyrrole-3-carboxylic acid ethyl ester | 258831-18-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: 4-(2-dimethylcarbamoyl-ethyl)-2-methyl-1H-pyrrole-3-carboxylic acid ethyl ester
• 英文别名: ethyl 4-[3-(dimethylamino)-3-oxopropyl]-2-methyl-1H-pyrrole-3-carboxylate
• CAS: 258831-18-4
• 化学式: C₁₃H₂₀N₂O₃
• 分子量: 252.313
• InChiKey: PYJAJPGOVGQGET-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  18
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  62.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(2-dimethylcarbamoyl-ethyl)-2-methyl-1H-pyrrole-3-carboxylic acid ethyl ester 在 lithium aluminium tetrahydride 、 三氯氧磷 作用下， 以 四氢呋喃 为溶剂， 生成 (3Z)-3-[[3-[3-(dimethylamino)propyl]-4,5-dimethyl-1H-pyrrol-2-yl]methylidene]-N-methyl-2-oxo-1H-indole-5-sulfonamide
  参考文献：
  名称：

  Design and synthesis of aminopropyl tetrahydroindole-based indolin-2-ones as selective and potent inhibitors of Src and Yes tyrosine kinase

  摘要：

  A novel series of substituted 3-[3-(aminopropyl)-4,5,6,7-tetrahydro-1H-indol-2-ylmethylene]-1,3-dihydro-indole-2-ones was discovered as potent inhibitors of the non-receptor tyrosine kinase Src and Yes. A structure-activity relationship was developed in order to optimize their potency and selectivity. Syntheses of these compounds are also described herein. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.09.069
• 作为产物：
  描述：

  4-(2-羧基-乙基)-2-甲基-1H-吡咯-3-羧酸乙酯 、 二甲胺 在 N,N'-羰基二咪唑 作用下， 以 四氢呋喃 、 DMF (N,N-dimethyl-formamide) 为溶剂， 反应 2.0h， 以85%的产率得到4-(2-dimethylcarbamoyl-ethyl)-2-methyl-1H-pyrrole-3-carboxylic acid ethyl ester
  参考文献：
  名称：

  Sulfonamide substituted indolinones as inhibitors of DNA dependent protein kinase (DNA-PK)

  摘要：

  本发明通常涉及放射增敏剂领域，这些放射增敏剂能够通过抑制DNA-PK（DNA-蛋白激酶）来增强放射疗法。具体而言，涉及抑制DNA-PK的磺胺基取代吲哚酮。

  公开号：

  US20040266843A1

文献信息

• 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors
  申请人：SUGEN Inc.

  公开号：US20040204407A1

  公开（公告）日：2004-10-14

  The present invention relates to 5-sulfonamido substituted indolinones that modulate the activity of protein kinases (“PKs”). The compounds of this invention are therefore useful in treating disorders related to abnormal PK activity. Pharmaceutical compositions comprising these compounds, methods of treating diseases utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.

  本发明涉及调节蛋白激酶（“PKs”）活性的5-磺胺基取代吲哚酮。因此，本发明的化合物在治疗与异常PK活性相关的疾病方面是有用的。包括这些化合物的药物组合物、利用包括这些化合物的药物组合物治疗疾病的方法以及它们的制备方法也被披露。
• 3-methylidenyl-2-indolinone modulators of protein kinase
  申请人：Sugen, Inc.

  公开号：US20040024010A1

  公开（公告）日：2004-02-05

  The present invention relates to novel 3-methylidenyl-2-indolinone compounds and physiologically acceptable salts and prodrugs thereof which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.

  本发明涉及新型的3-甲基亚烯基-2-吲哚酮化合物及其生理上可接受的盐和前药，这些化合物可调节蛋白激酶的活性，因此预计在预防和治疗蛋白激酶相关的细胞疾病，如癌症方面具有用途。
• 3-Methylidenyl-2-indolinone modulators of protein kinase
  申请人：Sugen, Inc.

  公开号：US06531502B1

  公开（公告）日：2003-03-11

  The present invention relates to novel 3-methylidenyl-2-indolinone compounds and physiologically acceptable salts and prodrugs thereof which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.

  本发明涉及新型的3-甲基亚乙烯基-2-吲哚酮化合物及其生理上可接受的盐和前药，其调节蛋白激酶活性，因此预计在预防和治疗蛋白激酶相关的细胞疾病，如癌症方面有用。
• US6531502B1
  申请人：——

  公开号：US6531502B1

  公开（公告）日：2003-03-11
• US6855730B2
  申请人：——

  公开号：US6855730B2

  公开（公告）日：2005-02-15